Clinical Trial Update: Assessment Of Safety Of UK-390,957 [Phase 2, Phase 3]

View source ↗

Summary

Pfizer's UK-390,957 safety assessment across Phase 2 and Phase 3 for ejaculation-related conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ejaculation

Drugs mentioned

• UK-390,957

Snippet

Sponsor: Pfizer | Conditions: Ejaculation | Phase 2, Phase 3 | Status: COMPLETED